Our Platform for Alzheimer's Disease

At IXICO, we are dedicated to transforming the landscape of Alzheimer's Disease research through cutting-edge neuroimaging and biomarker analytics. Our AI-driven platform is designed to provide precise and actionable insights, helping to advance the understanding, diagnosis, and treatment of AD.

A series of blogs showcasing our insight and thoughts in AD clinical research

Association of Vascular Risk Factors and Cerebrovascular Pathology with Alzheimer Disease Pathologic Changes in Individuals Without Dementia

• Date: October 8^th 2024
• Presentation type: co-authored journal manuscript with the AMYPAD consortium in the journal Neurology
• Synopsis: investigation of links between vascular risk factors, cerebral small vessel disease, and amyloid levels and their combined effect on downstream AD biomarkers.
• Therapeutic Indication: Alzheimer’s disease (AD)
• Link

A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory Imaging applied to the Bio-Hermes Trial.

• Date: October 31^st 2024
• Presentation type: oral presentation at the 17^th Clinical Trials in Alzheimer’s Disease (CTAD) conference in Madrid, Spain.
• Synopsis: analysis of the Global Alzheimer’s Platform Bio-Hermes data to investigate how blood-based-biomarkers can be operationalised in conjunction with PET imaging.
• Therapeutic Indication: Alzheimer’s disease (AD)
• Link

AI-Driven Classification of Alzheimer’s Disease and Frontotemporal Dementia from Magnetic Resonance Imaging

• Date: April 4^th 2025
• Presentation type: oral presentation at the 40^th International Conference on Alzheimer’s Disease and Parkinson’s Disease (ADPD) in Vienna, Austria
• Synopsis: development and validation of novel AI-driven measurements to support differential diagnosis between AD and FTD from volumetric MRI.
• Therapeutic Indication: Alzheimer’s disease (AD); Frontotemporal dementia (FTD)
• Link

Imaging - Advancing Biomarker Research for Alzheimer’s Disease Diagnosis

• Date: April 17^th 2025
• Presentation type: invited editorial in the Journal for Clinical Studies
• Synopsis: editorial discussion on the multimodal use of PET imaging in combination with novel blood based biomarkers to support streamlined clinical trial delivery.
• Therapeutic Indication: Alzheimer’s disease (AD)
• Link

A concise guide on neuroimaging in Alzheimer’s clinical trials, covering protocol harmonisation, imaging biomarkers, data consistency, PET tracer logistics, and ARIA monitoring—supporting high-quality, standardised imaging across multi-site studies.

IXICO excels in AD imaging with advanced imaging biomarkers to quantify markers such as amyloid plaques, tau tangles, and brain atrophy. Our platform enhances the accuracy and efficiency of brain imaging measurements. We have supported over 20,000 brain scans collected through various AD research initiatives.

Executing a Multi-Arm Phase 1 Alzheimer's Disease Global Clinical Trial with Clinilabs and IXICO: In collaboration with Clinilabs, IXICO successfully executed a complex Phase 1 multicenter, multi-arm Alzheimer's Disease clinical trial. This trial leveraged IXICO's advanced imaging biomarkers and AI-driven platform to quantify key AD measurements, ensuring precise and reproducible volumetric brain segmentations. The collaboration demonstrated IXICO's capability to manage and analyze large-scale clinical trials, providing critical insights into drug safety, eligibility, and efficacy.